Leukemia Clinical Studies

Some of the many Cancer and Blood Disorders research opportunities available related to leukemia are listed below. Select a study to review a brief description and requirements. Parents or guardians of children who might be eligible are encouraged to inquire about enrollment. Contact information is provided at the end of each study.

Please note that Pilot and Phase I studies are the most experimental and should be considered only after other treatments or trials have been attempted without success.

Thank you for exploring these opportunities and helping us to find cures and prevent childhood disease.

Clinical Studies

Researchers

Acute Lymphoblastic Leukemia and Localized Lymphoblastic Lymphoma Treatment with Blinatumomab as part of Chemotherapy – Phase III

AALL1731: A Study to Compare the Addition of Blinatumomab in Combination with Chemotherapy in Patients Diagnosed with Standard-risk B-cell Acute Lymphoblastic Leukemia, and the Treatment of Patients with Localized B-cell Lymphoblastic Lymphoma

Read more

Acute Lymphoblastic Leukemia Cell Banking Study

AALL05B1: Proper Protocols for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

Read more

Acute Lymphoblastic Leukemia Treatment with Blinatumomab in Combination with Nivolumab – Phase II

AALL1821: A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-cell Acute Lymphoblastic Leukemia

Read more

Acute Lymphoblastic Leukemia Treatment with Inotuzumab Ozogamicin as part of Chemotherapy – Phase III

AALL1732: A Study to Test if the Addition of Inotuzumab Ozogamicin to Standard Chemotherapy Treatment Improves Outcomes for Patients Diagnosed with National Cancer Institute High-Risk B-cell Acute Lymphoblastic Leukemia, or Standard-Risk B-cell Acute Lymphoblastic Leukemia with High-Risk Features

Read more

Acute Myeloid Leukemia Treatment with CPX-351 and Gilteritinib – Phase III

AAML1831: A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations

Read more

Acute Myeloid Leukemia Treatment with Risk-Adapted Chemotherapy for Patients With Down Syndrome – Phase III

AAML1531: Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Read more

Acute Promyelocytic Leukemia Treatment using Arsenic Trioxide and All Trans-Retinoic Acid – Phase III

AAML1331: Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia using Arsenic Trioxide and All Trans-Retinoic Acid

Read more

Children’s Oncology Group Long-Term Follow-up of Study Participants

ALTE05N1: Umbrella Long-Term Follow-Up Protocol for Participants with and without a History of Cancer

Read more

Children’s Oncology Group’s Project: EveryChild

APEC14B1: Project:Every Child, A Registry, Eligibility Screening, Biology and Outcome Study

Read more

Chronic Myeloid Leukemia Remission without TKI Medication – Phase II

AAML18P1: Stopping Tyrosine Kinase Inhibitors to Assess Treatment-Free Remission in Pediatric Chronic Myeloid Leukemia - Chronic Phase

Read more

Chronic Myeloid Leukemia Treatment with Bosutinib – Phase I/II

AAML1921: A Study of a Drug, Bosutinib, for Treating Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph+ Chronic Myeloid Leukemia

Read more

Fitness Program for Adolescent and Young Adult Childhood Cancer Survivors: The StepByStep Study – Phase III

ALTE2031: StepByStep: A Trial of a Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors

Read more

Fitness Program for Children and Adolescents Following Cancer Therapy – Phase III

ALTE1631: A Web-based Physical Activity Intervention among Children and Adolescents

Read more

Juvenile Myelomonocytic Leukemia Treatment using Trametinib – Phase II

ADVL1521: Study of the MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Read more

Solid Tumor and Leukemia Treatment with Larotrectinib – Phase II

ADVL1823: Larotrectinib for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias

Read more